Clinical Trial Database - NMD4C: The Neuromuscular Disease Network for Canada

Canadian Neuromuscular Clinical Trial Database

The Canadian Neuromuscular Clinical Trial Database has been created as an initiative of the NMD4C Clinical Trial Network in collaboration with Canadian neuromuscular clinical trial site teams to provide a comprehensive and reliable landscape of Canadian neuromuscular clinical trials. Monthly updates are provided by clinical research coordinators working at Canadian trial sites, ensuring the most current information is always available.

Search the database

This database addresses the need for

Accurate and up-to-date information: our database provides reliable details about recruiting and not yet recruiting neuromuscular clinical trials, including clinical trial site locations and contact information.
Collaboration: our database enables investigators to identify other sites conducting the same trial at different locations, fostering collaboration to address challenges and share best practices.
Streamlined patient referral: our database can be used as a tool to facilitate patient referral to appropriate clinical trials and/or clinical sites.

Explore the Clinical Trial Database

Database Legend

Disease Name	Table Abbreviation
Amyloid Transthyretin Amyloidosis	ATTR
Charcot-Marie-Tooth Syndrome	CMT
Chronic Inflammatory Demyelinating Polyradiculoneuropathy	CIDP
Congenital Myasthenic Syndromes	CMS
Congenital Myotonic Dystrophy	CDM
Dermatomyositis	DM
Duchenne Muscular Dystrophy	DMD
Facioscapulohumeral Muscular Dystrophy	FSHD
Friedreich Ataxia	FA
Generalized Myasthenia Gravis	gMG
Idiopathic Inflammatory Myopathy	IIM
Limb-Girdle Muscular Dystrophy	LGMD
Multifocal Motor Neuropathy	MMN
Myotonic Dystrophy 1	DM1
Oculopharyngeal Muscular Dystrophy	OPMD
Spinal Muscular Atrophy	SMA
Sporadic Inclusion Body Myositis	sIBM
X-linked Myotubular Myopathy	XLMTM

Filters

Disease/Condition	Title	Sponsor and Treatment	Pediatric/Adult	Site	Location	Recruitment status	Principal Investigator	Contact
DMD	The Expanded Duchenne Muscular Dystrophy (DMD) Natural History Study: Longitudinal Study of the Relationship Between Impairment, Activity Limitation, Participation and Quality of Life (eDNHS)	UC Davis / Sarepta	Pediatric	Alberta's Children Hospital	Calgary, AB	Recruiting	Jean Mah	Julie Dao
DMD	A phase 2 study to assess the efficacy, safety, tolerability, and pharmacokinetics of NS-089/NCNP-02 (Brogidirsen) in boys with Duchenne muscular dystrophy (DMD)	NS Pharma - NS-089/NCNP-02-201	Pediatric	Alberta's Children Hospital	Calgary, AB	Not yet recruiting	Jean Mah	Julie Dao
DMD	NS-050/NCNP-03 in Boys With DMD (Meteor50)	NS Pharma - NS-050/NCNP-03	Pediatric	Alberta's Children Hospital	Calgary, AB	Not yet recruiting	Jean Mah	Julie Dao
DMD	A Phase 1/2 Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Intravenous RGX-202 Gene Therapy in Males with Duchenne Muscular Dystrophy (DMD)	REGENXBIO Inc. - RGX-202 (AAV8.Spc5-12.microdystrophin)	Pediatric	Alberta's Children Hospital	Calgary, AB	Not yet recruiting	Jean Mah	Israt Yasmeen
SMA	A Registry-Based Parallel Group Randomized-Controlled Trial of an Upper Limb Exergaming Intervention for Children and Adolescents with Spinal Muscular Atrophy, with an Optional Open-Label Extension	Research Institute- McGill University Helath Health Centre	Pediatric	Alberta's Children Hospital	Calgary, AB	Recruiting	Jean Mah	Julie Dao
ATTR	Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis (MaesTTRo)	AstraZeneca	Adult	Centre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM)	Montreal, QC	Not yet recruiting	0	Amélie Bujold
FA	Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study (UNIFAI)	Natural History Study	Adult and Pediatric	Centre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM)	Montreal, QC	Recruiting	Antoine Duquette	Martine Comeau
FA	Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia	Lexeo Therapeutics - LX2006 (AAVrh.10hFXN)	Adult and Pediatric	Centre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM)	Montreal, QC	Recruiting	Antoine Duquette	Martine Comeau
CDM	Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy (REACH CDM X)	AMO Pharma Limited - Tideglusib	Pediatric	Children's Hospital of Eastern Ontario (CHEO)	Ottawa, ON	Recruiting	Hanns Lochmüller	Emilie Hill-Smith
DMD	Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy (ULYSSES)	Italfarmaco - Givinostat	Pediatric	Children's Hospital of Eastern Ontario (CHEO)	Ottawa, ON	Recruiting	Hugh McMillan	Emilie Hill-Smith
SMA	A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy (PUPFISH)	Hoffmann-La Roche - Risdiplam	Pediatric	Children's Hospital of Eastern Ontario (CHEO)	Ottawa, ON	Recruiting	Hugh McMillan	Prachi Inamdar
DM1	Music Intervention for Brain-Heart Disease in Myotonic Dystrophy Type 1 (DM1)	Hanns Lochmüller	Pediatric	Children's Hospital of Eastern Ontario (CHEO)	Ottawa, ON	Recruiting	Hanns Lochmüller	Tamara Burgess
DMD	A Phase 1/2 Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Intravenous RGX-202 Gene Therapy in Males with Duchenne Muscular Dystrophy (DMD)	REGENXBIO Inc. - RGX-202 (AAV8.Spc5-12.microdystrophin)	Pediatric	Children's Hospital of Eastern Ontario (CHEO)	Ottawa, ON	Recruiting	Hugh McMillan
gMG	A Long-term, Single-Arm, Open-label, Multicenter, Follow-on Trial of ARGX-113-2006 to Evaluate Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis	Argenx - Efgartigimod	Pediatric	British Columbia Children's Hospital	Vancouver, BC	Recruiting	Kathryn Selby	Dora Xiong
DMD	Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy (ULYSSES)	Italfarmaco - Givinostat	Pediatric	British Columbia Children's Hospital	Vancouver, BC	Recruiting	Kathryn Selby	Gabe Massarotto
DMD	A Phase 1/2 Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Intravenous RGX-202 Gene Therapy in Males with Duchenne Muscular Dystrophy (DMD)	REGENXBIO Inc. - RGX-202 (AAV8.Spc5-12.microdystrophin)	Pediatric	British Columbia Children's Hospital	Vancouver, BC	Recruiting	Kathryn Selby	Nela Martic
DMD	A phase 2 study to assess the efficacy, safety, tolerability, and pharmacokinetics of NS-089/NCNP-02 (Brogidirsen) in boys with Duchenne muscular dystrophy (DMD)	NS Pharma - NS-089/NCNP-02-201	Pediatric	British Columbia Children's Hospital	Vancouver, BC	Recruiting	Kathryn Selby	Gabe Massarotto
DMD	NS-050/NCNP-03 in Boys With DMD (Meteor50)	NS Pharma - NS-050/NCNP-03	Pediatric	British Columbia Children's Hospital	Vancouver, BC	Recruiting	Kathryn Selby	Gabe Massarotto
SMA	A Registry-Based Parallel Group Randomized-Controlled Trial of an Upper Limb Exergaming Intervention for Children and Adolescents with Spinal Muscular Atrophy, with an Optional Open-Label Extension	Research Institute- McGill University Helath Health Centre	Pediatric	British Columbia Children's Hospital	Vancouver, BC	Recruiting	Kathryn Selby	Nela Martic
FA	A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old	Biogen-Omaveloxolone	Pediatric	CHU de Québec	Quebec City, QC	Recruiting	Nicolas Chrestian	Davy Eng
gMG	Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis	Alexion Pharmaceuticals - ALXN1720	Adult	CHU de Québec*	Quebec City, QC	Recruiting	Annie Dion	Alexandra Simard
MMN	A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy (Empassion)	Argenx - Efgartigimod	Adult	CHU de Québec	Quebec City, QC	Recruiting	Annie Dion	Alexandra Simard
oMG	A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis	Argenx-Efgartigimod PH20 SC	Adult	CHU de Québec	Quebec City, QC	Recruiting	Annie Dion	Alexandra Simard
CIDP	A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Sanofi - Riliprubart	Adult	CHU de Québec	Quebec City, QC	Recruiting	Annie Dion	Alexandra Simard
CIDP	A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work	Sanofi - Riliprubart	Adult	CHU de Québec	Quebec City, QC	Recruiting	Annie Dion	Alexandra Simard
DM1	A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study of PGN-EDODM1 in Adult Participants with Myotonic Dystrophy Type 1 (FREEDOM2-DM1)	PepGen - PGN-EDODM1	Adult	CIUSSS du Saguenay-Lac-Saint-Jean	Saguenay, QC	Recruiting	Jean-Denis Brisson	Valerie Harvey
DM1	A Phase 1/2a Double-Blind, Placebo-controlled, Single- and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of Intravenous Administration of ATX-01 In Male and Female Participants aged 18 to 64 with Classic Myotonic Dystrophy Type 1 (DM1)	Arthrex - ATX-01	Adult	CIUSSS du Saguenay-Lac-Saint-Jean	Saguenay, QC	Recruiting	Jean-Denis Brisson	Valerie Harvey
DM1	An Open-Label Extension Study Evaluating Safety and Pharmacokinetics in Participants with Myotonic Dystrophy Type 1	PepGen - PGN-EDODM1	Adult	CIUSSS du Saguenay-Lac-Saint-Jean	Saguenay, QC	Not yet recruiting	Jean-Denis Brisson	Valerie Harvey
DM1	A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of DYNE-101 Administered to Participants with Myotonic Dystrophy Type 1	DYNE101-DM1-301	Adult	CIUSSS du Saguenay-Lac-Saint-Jean	Saguenay, QC	Not yet recruiting	Jean-Denis Brisson	Valerie Harvey
SMA	Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy (SYNAPSE-SMA)	NMD Pharma A/S - NMD670	Adult	Heritage Medical Research Clinic (HMRC)	Calgary, AB	Recruiting	Lawrence Korngut	Janet Petrillo
FSHD	Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD) (MOVE FSHD)	University of Kansas Medical Center - NA	Adult	Heritage Medical Research Clinic (HMRC)	Calgary, AB	Recruiting	Lawrence Korngut	Carissa Wong/Janet Petrillo
DM1	A Clinical Study of PGN-EDODM1 in People with Myotonic Dystrophy Type 1	PepGen - PGN-EDODM2	Adult	Heritage Medical Research Clinic (HMRC)	Calgary, AB	Recruiting	Gerald Pfeffer	Janet Petrillo
SMA	Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy (SYNAPSE-SMA)	NMD Pharma A/S - NMD670	Adult	Genge Partners Inc.	Montreal, QC	Recruiting	Erin O'Ferrall	Vincent Etten
MMN	A PHASE 2, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOMETRICS, AND EFFICACY OF DNTH103 IN ADULTS WITH MULTIFOCAL MOTOR NEUROPATHY (MOMENTUM)	Dianthus Therapeutics - DNTH103	Adult	Genge Partners Inc.	Montreal, QC	Recruiting	Angela Genge	Vincent Etten
CIDP	A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults with Chronic Inflammatory Demyelinating Polyneuropathy	argenx - Empasiprubart	Adult	Genge Partners Inc.	Montreal, QC	Not yet recruiting	Maxime Bérubé	Vincent Etten
FSHD	A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)	Avidity - AOC-1020 (Del-brax)	Adult	Genge Partners Inc.	Montreal, QC	Not yet recruiting	Angela Genge	Vincent Etten
CDM	Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy (REACH CDM X)	AMO Pharma Limited - Tideglusib	Pediatric	Children's Hospital London Health Sciences Centre (LHSC)	London, ON	Enrolling by invitation	Craig Campbell	Rhiannon Hicks
DMD	Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy (ULYSSES)	Italfarmaco - Givinostat	Pediatric	Children's Hospital London Health Sciences Centre (LHSC)	London, ON	Recruiting	Craig Campbell	Rhiannon Hicks
DMD	A Phase 1/2 Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Intravenous RGX-202 Gene Therapy in Males with Duchenne Muscular Dystrophy (DMD)	REGENXBIO Inc. - RGX-202 (AAV8.Spc5-12.microdystrophin)	Pediatric	Children's Hospital London Health Sciences Centre (LHSC)	London, ON	Recruiting	Craig Campbell	Rhiannon Hicks
DMD	A phase 2 study to assess the efficacy, safety, tolerability, and pharmacokinetics of NS-089/NCNP-02 (Brogidirsen) in boys with Duchenne muscular dystrophy (DMD)	NS Pharma - NS-089/NCNP-02-201	Pediatric	Children's Hospital London Health Sciences Centre (LHSC)	London, ON	Recruiting	Craig Campbell	Rhiannon Hicks
DMD	NS-050/NCNP-03 in Boys With DMD (Meteor50)	NS Pharma - NS-050/NCNP-03	Pediatric	Children's Hospital London Health Sciences Centre (LHSC)	London, ON	Recruiting	Craig Campbell	Rhiannon Hicks
DMD	A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intravenous Doses of BMN 351 in Participants with Duchenne Muscular Dystrophy	BioMarin Pharmaceutical - BMN 351	Pediatric	Children's Hospital London Health Sciences Centre (LHSC)	London, ON	Not yet recruiting	Craig Campbell	Rhiannon Hicks
gMG	A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (RemeMG)	RemeGen Co - Telitacicept	Adult	London	London/ON	Enrolling by invitation	0
oMG	A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis (ADAPT oculus)	argenx - Efgartigimod	Adult	London	London/ON	Enrolling by invitation	Michael Nicole
gMG	A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis (RELIEVE)	Novartis Pharmaceuticals - Remibrutinib	Adult	London	London/ON	Enrolling by invitation	0
gMG	Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)	Alexion Pharmaceuticals	Adult	London	London/ON	Enrolling by invitation	0
FSHD	A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DUX4 in Adult Patients with Facioscapulohumeral Muscular Dystrophy Type 1	Arrowhead Pharmaceuticals ARO-DUX4	Adult	McGill University - Montreal Neurological Institute/Hospital (MNI)	Montreal, QC	Not yet recruiting	Angela Genge	NM research team
CIDP	A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work (MOBILIZE)	Sanofi - Riliprubart	Adult	McGill University - Montreal Neurological Institute/Hospital (MNI)	Montreal, QC	Recruiting	Rami Massie	NM research team
DM1	Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy	Arrowhead Pharmaceuticals - ARO-DM1	Adult	McGill University - Montreal Neurological Institute/Hospital (MNI)	Montreal, QC	Not yet recruiting	0	NM research team
CIDP	A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (VITALIZE)	Sanofi - Riliprubart	Adult	McGill University - Montreal Neurological Institute/Hospital (MNI)	Montreal, QC	Recruiting	Rami Massie	NM research team
CMT	A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A	Novartis Pharmaceuticals - EDK060	Adult	McGill University - Montreal Neurological Institute/Hospital (MNI)	Montreal, QC	Recruiting	Rami Massie	NM research team
IMNM / DM	Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)	Chugai Pharmaceutical - RAY121	Adult	McGill University - Montreal Neurological Institute/Hospital (MNI)	Montreal, QC	Recruiting	Erin O'Ferrall	NM research team
DM1	A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM2-DM1)	PepGen Inc - PGN-EDODM1	Adult	McGill University - Montreal Neurological Institute/Hospital (MNI)	Montreal, QC	Recruiting	Erin O'Ferrall	NM research team
DMD	Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy (ULYSSES)	Italfarmaco - Givinostat	Pediatric	Holland Bloorview Kids Rehabilitation Hospital	Toronto, ON	Recruiting	Laura McAdam	Lina Buelvas
SMA	A Registry-Based Parallel Group Randomized-Controlled Trial of an Upper Limb Exergaming Intervention for Children and Adolescents with Spinal Muscular Atrophy, with an Optional Open-Label Extension	Research Institute- McGill University Helath Health Centre	Pediatric	McGill University Health Centre - Glen Site	Montreal, QC	Recruiting	Maryam Oskoui	Mbaye Ndiaye
FA	A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old	Biogen-Omaveloxolone	Pediatric	McGill University Health Centre - Glen Site	Montreal, QC	Not yet recruiting	Maryam Oskoui	Mbaye Ndiaye
CMS	Multicenter, multinational, natural history study in participants with congenital myasthenic syndromes due to mutations in DOK7, MUSK, AGRN, or LRP4	Natural History Study	Adult	Ottawa Hospital Research Institute (OHRI)	Ottawa, ON	Recruiting	Hanns Lochmüller	Mahsa Haghighi
gMG	A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis	Janssen Research & Development, LLC - Nipocalimab	Adult	Ottawa Hospital Research Institute (OHRI)	Ottawa, ON	Not yet recruiting	Ariel Breiner	Isabel Horton
gMG	A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patients with generalized Myasthenia Gravis, followed by an open-label extension phase	Novartis Research and Development- remibrutinib	Adult	Ottawa Hospital Research Institute (OHRI)	Ottawa, ON	Recruiting	Ariel Breiner	Isabel Horton
DM1	Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1 (FREEDOM-DM2)	PepGen - PGN-EDODM1	Adult	Ottawa Hospital Research Institute (OHRI)	Ottawa, ON	Recruiting	Hanns Lochmüller	Jessica MacGregor
FSHD	Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD) (MOVE FSHD)	University of Kansas Medical Center - NA	Adult	Ottawa Hospital Research Institute (OHRI)	Ottawa, ON	Recruiting	Hanns Lochmüller	Jessica MacGregor
NMD	The Canadian Neuromuscular Disease Registry	University of Calgary	Adult	Ottawa Hospital Research Institute (OHRI)	Ottawa, ON	Recruiting	Hanns Lochmüller	Jessica MacGregor
CMT	A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A	Novartis Pharmaceuticals - EDK060	Adult	Ottawa Hospital Research Institute (OHRI)	Ottawa, ON	Recruiting	Alberto Aleman	Kathryn Beaudry
DMD	A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)	Solid Biosciences Inc. - SGT-003	Pediatric	The Hospital for Sick Children (SickKids)	Toronto, ON	Recruiting	Hernan Gonorazky	Ana Stosic
SMA/DMD	The Canadian Neuromuscular Disease Registry (CNDR)	University of Calgary	Pediatric/Adult	The Hospital for Sick Children (SickKids)	Toronto, ON	Recruiting	Hernan Gonorazky	Magdalena Lovaglio
DM1	Review of Patients with Congenital Myotonic Dystrophy type 1	0	Pediatric	The Hospital for Sick Children (SickKids)	Toronto, ON	Recruiting	Hernan Gonorazky	Magdalena Lovaglio
SBMA	Understanding the prevalence, clinical features, and genetics of spinal-bulbar muscular atrophy (SBMA) in people of Indigenous descent	Kennedy Disease Association	Adult	Univerisity of Saskatchewan	Saskatoon, SK	Recruiting	Kerri Schellenberg	Joanne Boyer
ATTR	MaesTTRo: A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients with Amyloid Transthyretin (ATTR) Amyloidosis (D8450R00003)	AstraZeneca AB - D8450R00003	Adult	Vancouver General Hospital	Vancouver, BC	Recruiting	Michelle Mezei	Deborah Kraus
DMD	A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)	Solid Biosciences Inc. - SGT-003	Pediatric	The Hospital for Sick Children (SickKids)	Vancouver, BC	Recruiting	Kathryn Selby	Nela Martic

*Information from ClinicalTrials.gov

Our websites and training platforms will be undergoing maintenance from December 22 - 26 and 29 - 31, 2025. During these days, access may be limited.

NMD4C: The Neuromuscular Disease Network for Canada

Canadian Neuromuscular Clinical Trial Database

This database addresses the need for

Explore the Clinical Trial Database

Filters

Funded by:

Sign up for the NMD4C newsletter